Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. C5 precursor is first processed by the removal of 4 basic residues, forming two chains, beta and alpha, linked by a disulfide bond. C5 convertase activates C5 by cleaving the alpha chain, releasing C5a anaphylatoxin and generating C5b (beta chain + alpha chain). Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5bC6 complex is the foundation upon which the lytic complex is assembled. The C5a anaphylatoxin interacts with C5AR1 and tick complement inhibitor. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation. - Proteine/Peptide
Molekulargewicht:
73.9 kDa (beta chain) & 138.9 kDa (alpha chain)
Immobilized Human Complement C5 Protein, Fc Tag (Cat. No. CO5-H5253) at 1 µg/mL (100 µL/well) can bind Monoclonal Anti-Human C5a Human Antibody, Human IgG1 with a linear range of 0.5-4 ng/mL (QC tested).
Immobilized Human Complement C5 Protein, Fc Tag (Cat. No. CO5-H5253) at 1 µg/mL (100 µL/well) can bind Eculizumab Biosimilar with a linear range of 0.1-2 ng/mL (Routinely tested).
Human Complement C5 Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
